CAR T-cell-derived exosomes for cell-free cancer immunotherapy
Explore innovative CAR T-cell-derived exosomes as a cell-free cancer immunotherapy, offering precision targeting and reduced cytokine release risk, with the ability to penetrate solid tumors.
Overview
CAR T-cell-derived exosomes represent a revolutionary approach in cancer immunotherapy. These extracellular vesicles (EVs) inherit properties from engineered CAR T-cells, maintaining CAR specificity and antitumor activity. Designed to target a range of antigens such as HER2, GPC3, and EGFRvIII, these exosomes provide precision targeting and are engineered to overcome the immune-suppressive tumor microenvironment. By lacking PD-1 and CTLA-4, they act as off-the-shelf products with reduced alloreactivity, minimizing the risk of Cytokine Release Syndrome and enhancing solid tumor penetration.
Technical specifications
-
Key features:
- Derived from CAR T-cells targeting antigens like HER2, GPC3, and EGFRvIII
- Lack of PD-1 and CTLA-4 enables overcoming suppressive tumor microenvironments
- Absence of MHC I/II reduces risk of alloreactivity
- Engineered for precision targeting and solid tumor penetration
-
Research and validation:
- In vitro validations confirmed the presence of CAR constructs in EVs
- Cytotoxicity assays demonstrated target-specific effects
- Future stages include in vivo validation and scalability assessments
Technology readiness level
Currently at Technology Readiness Level 3, this innovation is in the proof-of-principle stage, with ongoing development focused on in vitro and in vivo validation, as well as scalability for commercial application.
About Elbeltagytherapeutics
Elbeltagy Therapeutics Co. is a biotechnology startup headquartered in Mansoura, Egypt, dedicated to advancing regenerative medicine. The company focuses on the utilization of dental-derived mesenchymal stem cells (MSCs) and engineered extracellular vesicles (EVs), maintaining a strong emphasis on clinical translation. In collaboration with the Healthcare Professionals Network for Egypt (HPNE), the company is working to establish a prototype Dental Pulp Stem Cell (DPSC) biobank in Egypt, designed to facilitate the isolation, preservation, and distribution of high-quality stem cells and EVs for research and future medical applications.
This initiative aims to create a Good Manufacturing Practice (GMP)-ready infrastructure that functions as a national and regional reference center, positioning Egypt within the global regenerative medicine ecosystem. The organization's efforts are designed to support translational research and standardize biobanking practices. Beyond its primary research and development focus, the company also operates a cosmetic product line branded as EVOXIR. By aligning with international biobanking standards, Elbeltagy Therapeutics seeks to foster a sustainable and scalable model for regenerative medicine development in developing countries.
delivered to your inbox.